We provide you with 20 years of free, institutional-grade data for RPHM stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RPHM. Explore the full financial landscape of RPHM stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about RPHM stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Reneo Pharmaceuticals, Inc.(NASDAQ:RPHM) 
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patie...
Website: http://reneopharma.com
Founded: 2014
CEO: Gregory J. Flesher
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends